The pathogenesis of primary progressive multiple sclerosis: antibody-mediated attack and no repair?
Primary progressive multiple sclerosis (MS) differs from the more common form of MS which has an initial relapsing-remitting course in a number of ways, including pathological features, clinical course, differential diagnosis and response to treatment. The lesions in primary progressive MS tend to be more diffuse, less inflammatory and less likely to remyelinate than those occurring in relapsing-remitting MS and secondary progressive MS; there are also fewer focal lesions in the brain in primary progressive MS. Recent evidence suggests that antibodies to central nervous system (CNS) antigens have an important role in disease progression. Such antibodies could cause demyelination, inhibit remyelination and cause axonal destruction. Ongoing immune attack by autoantibody and lack of CNS repair could be responsible for the gradually increasing disability in primary progressive MS. Further research on the B-cell and autoantibody response in primary progressive MS might lead to advances in diagnosis and treatment. Inhibition of autoantibody production by inducing B-cell apoptosis with rituximab is a potential new therapy for primary progressive MS.
Pender
Michael P
MP
School of Medicine, Neuroimmunology Research Centre, The University of Queensland, Australia. m.hawes@uq.edu.au
D001323:Autoantibodies / Q000378:metabolism*; D002490:Central Nervous System / Q000276:immunology*; D018450:Disease Progression; D006801:Humans; D020528:Multiple Sclerosis, Chronic Progressive / Q000209:etiology* / Q000276:immunology*
D001323:Autoantibodies